1. Home
  2. VCEL vs CMMB Comparison

VCEL vs CMMB Comparison

Compare VCEL & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VCEL
  • CMMB
  • Stock Information
  • Founded
  • VCEL 1989
  • CMMB 2004
  • Country
  • VCEL United States
  • CMMB Israel
  • Employees
  • VCEL N/A
  • CMMB N/A
  • Industry
  • VCEL Biotechnology: Biological Products (No Diagnostic Substances)
  • CMMB Biotechnology: Pharmaceutical Preparations
  • Sector
  • VCEL Health Care
  • CMMB Health Care
  • Exchange
  • VCEL Nasdaq
  • CMMB Nasdaq
  • Market Cap
  • VCEL N/A
  • CMMB 37.3M
  • IPO Year
  • VCEL 1997
  • CMMB N/A
  • Fundamental
  • Price
  • VCEL $57.09
  • CMMB $1.96
  • Analyst Decision
  • VCEL Strong Buy
  • CMMB Strong Buy
  • Analyst Count
  • VCEL 7
  • CMMB 2
  • Target Price
  • VCEL $63.29
  • CMMB $7.50
  • AVG Volume (30 Days)
  • VCEL 346.3K
  • CMMB 77.2K
  • Earning Date
  • VCEL 02-27-2025
  • CMMB 03-06-2025
  • Dividend Yield
  • VCEL N/A
  • CMMB N/A
  • EPS Growth
  • VCEL N/A
  • CMMB N/A
  • EPS
  • VCEL 0.07
  • CMMB N/A
  • Revenue
  • VCEL $226,844,000.00
  • CMMB N/A
  • Revenue This Year
  • VCEL $23.08
  • CMMB N/A
  • Revenue Next Year
  • VCEL $21.58
  • CMMB N/A
  • P/E Ratio
  • VCEL $794.21
  • CMMB N/A
  • Revenue Growth
  • VCEL 22.48
  • CMMB N/A
  • 52 Week Low
  • VCEL $39.12
  • CMMB $0.55
  • 52 Week High
  • VCEL $63.00
  • CMMB $2.55
  • Technical
  • Relative Strength Index (RSI)
  • VCEL 46.07
  • CMMB 46.64
  • Support Level
  • VCEL $54.45
  • CMMB $1.86
  • Resistance Level
  • VCEL $63.00
  • CMMB $2.06
  • Average True Range (ATR)
  • VCEL 2.17
  • CMMB 0.14
  • MACD
  • VCEL -0.41
  • CMMB -0.02
  • Stochastic Oscillator
  • VCEL 30.88
  • CMMB 30.30

About CMMB Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.

Share on Social Networks: